Preventing Depression Recurrence in Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Part A: Prevention of Depression Recurrence in Diabetes
- To determine the efficacy of maintenance antidepressant medication in preventing or delaying recur-rence of major depression in diabetes.
- To determine the relationship of sustained depression remission to social, occupational, and global func-tioning, and to quality of life and compliance with diabetes treatment.
- To determine clinical features predictive of depression recurrence in diabetes.
Part B. Longitudinal Study of the Interrelationship of Glycemic Control and Depression
- To determine the effects of depression remission and recurrence on glycemic control.
- To determine the efficacy of maintenance antidepressant medication in producing sustained benefits in glycemic control.
- To determine the interrelationship of daily mood with blood glucose and the effect of maintenance treatment on this relationship.
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-80
- Type 1 or Type 2 Diabetes
- Screen positive for depression
Exclusion Criteria:
- Are pregnant or lactating
- Are known to be hypersensitive to the drug
- Have a recent history of myocardial infarction or unstable heart disease
- Have severe hepatic disease or renal impairment (serum creatinine > 3 mg/dl)
- The subset of patients with psychiatric disorders thought to affect management (e.g., schizophrenia, alcohol and drug dependence) will also be excluded from participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Patrick J Lustman, Ph.D., Washington University School of Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Mood Disorders
- Endocrine System Diseases
- Disease Attributes
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Recurrence
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Sertraline
Other Study ID Numbers
Other Study ID Numbers
- 96-0806 (completed)
- DK53060
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.